<DOC>
	<DOCNO>NCT01732211</DOCNO>
	<brief_summary>The study propose evaluate safety , tolerability , efficacy PD 0360324 subject chronic pulmonary sarcoidosis inadequately treat standard care therapy .</brief_summary>
	<brief_title>A Phase 2 , Safety , Tolerability , Efficacy Study PD 0360324 Chronic Pulmonary Sarcoidosis</brief_title>
	<detailed_description>The trial terminate prematurely Mar 24 , 2014 due business decision . The decision terminate trial base clinical safety efficacy concern .</detailed_description>
	<mesh_term>Sarcoidosis</mesh_term>
	<mesh_term>Sarcoidosis , Pulmonary</mesh_term>
	<criteria>Diagnosis biopsyproved chronic pulmonary sarcoidosis either Stage 2 Stage 3 least 1 year ; Forced Vital Capacity ( FVC ) lung assessment &gt; 40 % &lt; = 80 % predict normal value screen ; age 2175 year age ; treatment stable ( longer 4 week ) regimen corticosteroid ( 10 30 mg prednisone ) least 3 month prior Screening ; ( antiinflammatory drug may permit define study protocol ) History pulmonary ( lung ) disease sarcoidosis ( ex , asthma require maintenance treatment , chronic obstructive pulmonary disease ( COPD ) ) ; Pulmonary hypertension , significant lung fibrosis , chronic infection ( eg , TB , HIV ) ; treatment biologic antiinflammatory/immunomodulatory drug ; active smoker ; class 3 4 congestive heart failure ; cancer , history cancer within past 5 year ; history ischemic heart disease , heart attack , stroke , heart muscle disease ; liver disease ; history alcohol drug abuse</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Phase 2</keyword>
	<keyword>Randomized</keyword>
	<keyword>Double Blind</keyword>
	<keyword>Placebo Controlled</keyword>
	<keyword>Parallel</keyword>
	<keyword>20 Week Safety</keyword>
	<keyword>Tolerability</keyword>
	<keyword>Efficacy Study</keyword>
</DOC>